CTIS.eu › Cities › France › Marseille
Marseille
France
1,485 total trials
664 recruiting
Filter these 1,485 trials by phase, condition, sponsor and more.
Open in Search →
2023-510150-17-00
4
2024-12-11
Active, refractory systemic lupus erythematosus (SLE), and active, re
2024-516109-21-00
5
2024-12-09
Polycythaemia Vera (PV)
2023-508960-31-00
5
2024-12-03
Metastatic HER2-positive breast cancer
2023-508148-23-01
5
2024-12-02
chronically occluded coronary artery
2023-509673-22-00
9
2024-12-02
Neuroblastoma
2023-508400-38-00
4
2024-11-29
meningioma
2024-510718-34-00
11
2024-11-29
Membranous nephropathy
2024-512895-36-00
5
2024-11-25
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
2024-512113-41-00
5
2024-11-20
Severe Asthma
2023-509585-38-00
9
2024-11-19
Ependymoma
2024-511313-38-00
4
2024-11-17
Soft Tissue Sarcoma
2023-505232-36-00
5
2024-11-15
Essential thrombocythemia
2024-518813-24-00
1
2024-11-12
Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-
2023-508704-37-00
5
2024-11-08
Stroke
2024-514567-26-00
7
2024-11-08
glioblastoma
2023-507178-41-00
9
2024-11-07
Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults
2024-514886-21-00
6
2024-11-06
Pemphigus diseases (Pemphigus Vulgaris - PV and Pemphigus Foliaceus
(P
2024-516242-19-00
5
2024-11-05
lupus nephritis
2023-504620-26-00
4
2024-11-04
Triple negative breast cancer
2024-514899-41-00
4
2024-10-31
Breast cancer
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
2024-511453-22-00
1
2024-10-28
Participants with Advanced Solid Malignancies
2024-516101-23-00
5
2024-10-28
Sarcoidosis
Showing 529–552 of 1,485 trials